Industry observers argue that medical technology companies can tap into increased healthcare spending among emerging economies while the U.S. market has matured and could experience slower growth. Looking ahead, in the years through 2024, spending growth is projected to average 5.8% and peak at 6.3% in 2020.
“Equal-weight strategies are often criticized because their success is usually attributable to larger exposure to small caps. Still, it is hard to argue with RYH’s track record, which includes topping the Health Care Select Sector SPDR (NYSEArca:XLV) by almost 700 basis points over the past three years while displaying comparable volatility,” according to InvestorPlace.
Related: 3 Strategic Reasons Advisors Should Adopt Factor-Based ETFs
RYH, which is nearly 11 years old, has almost $710 million in assets under management and holds 61 stocks.
For more on smart beta ETFs, visit our Smart Beta Channel.
Tom Lydon’s clients own shares of RSP.